Cartesian Therapeutics (RNAC) Tax Provisions (2021 - 2022)
Cartesian Therapeutics (RNAC) posted quarterly Tax Provisions of -$288000.0 for Q4 2022, down 308.7% year-over-year from $138000.0 in Q4 2021, and up 10.28% quarter-over-quarter from -$321000.0 in Q3 2022.
Powered by 
Analysis
Cartesian Therapeutics (RNAC) Tax Provisions (2021 - 2022) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Tax Provisions for 2 consecutive years, with -$288000.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Tax Provisions fell 308.7% year-over-year to -$288000.0; the TTM figure through Dec 2022 stood at $15.4 million (down 3.81% YoY), while the FY2025 annual figure was -$9.2 million, down 3166.67% from the prior year.
- Tax Provisions improved to -$288000.0 in Q4 2022 per RNAC's latest filing, from -$321000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $15.8 million in Q3 2021 and bottomed at -$321000.0 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Cartesian Therapeutics | 271.98 Mn | 271.98 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | -288,000.00 |
| Sep 30, 2022 | -321,000.00 |
| Dec 31, 2021 | 138,000.00 |
| Sep 30, 2021 | 15.83 Mn |